Aspira Women’s Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch
02 Mai 2024 - 2:00PM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced the formal launch of an updated OvaWatch ovarian cancer
risk assessment test following the completion of all appropriate
pre-launch activities.
Adnexal masses develop near the uterus, usually in or around the
ovaries, fallopian tubes, and neighboring connective tissues. Most
adnexal masses do not pose a serious threat to the health of a
woman and resolve on their own within a few months. Others will
require treatment or surgery. OvaWatch utilizes an AI-powered
algorithm to assess malignancy risk of adnexal masses when initial
clinical assessment indicates the mass is indeterminant or benign.
With a negative predictive value of 99%, OvaWatch can help
physicians confidently determine the appropriate care plan over
time.
“We are proud to be able to meaningfully enhance the OvaWatch
offering with the longitudinal monitoring feature,” said Dr. Sandra
Milligan, President of Aspira Women’s Health. “More than 1.2
million women will present with an adnexal mass each year, and
OvaWatch offers doctors and their patients a powerful tool to
assess malignancy risk when it is identified and over time. We
believe OvaWatch will help improve care decisions for women with
adnexal masses, especially when surgery may be unnecessary or
premature.”
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is a reflex
process of two FDA-cleared tests, Ova1® and Overa®, to assess the
risk of ovarian malignancy in women planned for surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking StatementsThis press release
contains forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve a number of risks and uncertainties. Such
forward-looking statements include statements regarding, among
other things, the timing and completion of any products in the
pipeline development and other statements that are predictive in
nature. Actual results could differ materially from those discussed
due to known and unknown risks, uncertainties, and other factors.
These forward-looking statements generally can be identified by the
use of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors that may cause
such differences include the satisfaction of customary closing
conditions related to the offering and the expected timing of the
closing of the offering. These and additional risks and
uncertainties are described more fully in the company’s filings
with the SEC, including those factors identified as “Risk Factors”
in our most recent Annual Report on Form 10-K, for the fiscal year
ended December 31, 2023. If any of these risks materialize or our
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There
may be additional risks that Aspira presently does not know, or
that Aspira currently believes are immaterial, that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Aspira’s expectations, plans, or forecasts of future events
and views as of the date of this press release. Subsequent events
and developments may cause the Company’s assessments to change.
However, while Aspira may elect to update these forward-looking
statements at some point in the future, Aspira expressly disclaims
any obligation to do so, except as required by law. These
forward-looking statements should not be relied upon as
representing Aspira’s assessments of any date after the date of
this press release. Accordingly, undue reliance should not be
placed upon the forward-looking statements.
Investor Relations Contact: Torsten
Hombeck, Ph.D. Chief Financial Officer Aspira Women’s
Health Investors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aspira Womans Health (NASDAQ:AWH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024